Withdrawal of therapy in non-renal systemic lupus erythematosus: Is this an achievable goal?

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.78, 2013, Pages

  Mosca, Marta ^a   Tani, Chiara ^a   Aringer, Martin ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Antimalarial drugs; Disease remission; Glucocorticoids; Immunosuppressive drugs; Systemic lupus erythematosus; Withdrawal

Indexed keywords

ANTIMALARIAL AGENT; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; PLACEBO; STEROID;

ARTICLE; COHORT ANALYSIS; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE EXACERBATION; DRUG WITHDRAWAL; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; PRIORITY JOURNAL; REMISSION; SURVIVAL; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT RESPONSE;

DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PATIENT SELECTION; RECURRENCE; REMISSION INDUCTION; RISK FACTORS; STEROIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84885713625     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. MAK A, CHEUNG MWL, CHIEW HJ, LIU Y, HO RC: Global trend of survival and damage of systemic lupus erythematosus: meta-analysis and meta-regression of observational studies from the 1950s to 2000s. Semin Arthritis Rheum 2012; 41: 830-9.
2. FANGTHAM M, PETRI M: 2013 Update: Hopkins Lupus Cohort. Curr Rheumatol Rep 2013; 15: 360.
3. URAMOTO KM, MICHET CJ, THUMBOO J, SUNKU J, O'FALLON MW, GABRIEL SE: Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum 1999; 42: 46-50.
4. UROWITZ MB, GLADMAN DD, IBANEZ D et al.: Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res 2012; 64: 132-7.
5. HERSH AO, VON SCHEVEN E, YAZDANY J et al.: Differences in long-term disease activity and treatment of adult patients with childhood and adult-onset systemic lupus erythematosus. Arthritis Care Res 2009; 61: 13-20.
6. MOSCA M, BOUMPAS DT, BRUCE IN et al.: Treat-to-target in systemic lupus erythematosus: where are we today?. Clin Exp Rheumatol 2012; 30 (Suppl. 73): S112-115.
7. GLADMAN DD, UROWITZ MB, RAHMAN P, IBAñEZ D, TAM LS: Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003; 30: 1955-9.
8. URIBE AG, McGWIN G, REVEILLE JD, ALARCON GS: What have we learned from a 10-year experience with the LUMINA (Lupus in Minorities; nature vs. nurture) cohort? Where are we heading? Autoimmunity Rev 2004; 3: 321-9.
9. IBAñEZ D, GLADMAN DD, UROWITZ MB: Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol 2005: 32: 824-7.
10. NOSSENT J, KISS E, ROZMAN B et al.: Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 2010; 19: 949-56.
11. UROWITZ MB, FELETAR M, BRUCE IN, IBAñEZ D, GLADMAN DD: Prolonged remission in systemic lupus erythematosus. J Rheumatol 2005; 32: 1467-72.
12. GILBOE IM, KVIEN TK, HUSBY G: Disease course in systemic lupus erythematosus: changes in health status, disease activity, and organ damage after 2 years. J Rheumatol 2001; 28: 266-74.
13. FERNáNDEZ M, CALVO-ALéN J, ALARCóN GS et al.: Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXI. Disease activity, damage accrual, and vascular events in pre-and postmenopausal women. Arthritis Rheum 2005; 52: 1655-64.
14. GINZLER EM, ANTONIADIS I: Clinical manifestations of systemic lupus erythematosus, measures of disease activity, and long-term complications. Curr Opin Rheumatol 1992; 4: 672-80.
15. MOON SJ, PARK HS, KWOK SK, JU JH, KIM HY, PARK SH: Predictors of end-stage renal disease and recurrence of lupus activity after initiation of dialysis in patients with lupus nephritis. Clin Exp Rheumatol 2013; 31: 31-9.
16. PETRI M, BARR SG, ZONANA-NACH A, MAGDER L: Measures of disease activity, damage, and health status: the Hopkins Lupus Cohort experience. J Rheumatol 1999; 26: 502-3.
17. GLADMAN DD, HIRANI N, IBAñEZ D, UROWITZ MB: Clinically active serologically quiescent systemic lupus erythematosus. J Rheumatol 2003; 30:1960-2.
18. EHRENSTEIN MR, CONROY SE, HEATH J, LATCHMAN DS, ISENBERG DA: The occurrence, nature and distribution of flares in a cohort of patients with systemic lupus erythematosus: a rheumatological view. Br J Rheumatol 1995; 34: 257-60.
19. ZONANA-NACACH A, SALAS M, SáNCHEZ ML, CAMARGO-CORONEL A, BRAVO-GATICA C, MINTZ G: Measurement of clinical activity of systemic lupus erythematosus and laboratory abnormalities: a 12-month prospective study. J Rheumatol 1995; 22: 45-9.
20. POSNIK J: Systemic lupus erythematosus. The effect of corticotropin and adrenocorticoid therapy on survival rate. California Med 1963; 98: 308-12.
21. ABOU ZAHR A, FANG H, MADGER LS, PETRI M: Predictors of corticosteroid tapering in SLE patients: the Hopkins Lupus Cohort. Lupus 2013; 22: 697-701.
22. THAMMER M, HERNAN MA, ZHANG Y, COTTER D, PETRI M: Relationship between prednisone, lupus activity and permanent organ damage. J Rheumatol 2009; 36: 560-4.
23. MOSCA M, TANI C, CARLI L, BOMBARDIERI S: Glucocorticoids in systemic lupus erythematosus. Clin Exp Rheumatol 2011; 29 (Suppl. 68): S126-129.
24. Ad Hoc Working Group on Steroid-Sparing Criteria in Lupus: Criteria for steroid-sparing ability of interventions in systemic lupus erythematosus: Report of a consensus meeting. Arthritis Rheum 2004; 50: 3427-31.
25. SHAH M, CHAUDHARI S, McLAUGHLIN TP et al.: Cumulative burden of oral corticosteroid adverse effects and the economic implications of corticosteroid use in patients with systemic lupus erythematosus. Clin Ther 2013; 35: 486-97.
26. HUSCHER-D, THIEILE K, GROMICA-IHLE E et al.: Dose-related patterns of glucocorticoidindiced side effects. Ann Rheum Dis 2009; 68: 1119-24.
27. RUIZ-IRASTORZA G, RAMOS-CASALS M, BRITO-ZERON P, KHAMASHTA MA: Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic literature review. Ann Rheum Dis 2010; 69: 20-8.
28. COSTEDOAT-CHALUMEAU N, GALICIER L, AUMAITRE O et al.: Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Ann Rheum Dis 2012; 0: 1-7. doi:10.1136/annrheumdis-2012-202322.
29. The Canadian Hydroxychloroquine Study Group: A randomized study of the effect of withdrawing hydroxchloroquine sulfate in systemic lupus erythematosus. New Engl J Med 1991; 324: 150-4.
30. ARINGER M, BURKHARDT H, BURMESTER GR et al.: Current state of evidence on 'offlabel' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland-a consensus report. Lupus 2012; 21: 386-401.
31. OGLESBY A, SHAUL AJ, POKORA T et al.: Adverse event burden, resource use, and costs associated with immunosuppressant medications for the treatment of systemic lupus erythematosus: a systematic literature review. Int J Rheumatol 2013; 2013: 347-520.
32. PEGO-REIGOSA JM, COBO-IBáñEZ T, CALVO-ALéN J et al.: Efficacy and safety of nonbiologic immunusuppresants in the treatment of non-renal systemic lupus erythematosus: A systematic review. Arthritis Care Res (Hoboken) 2013 Apr 22 [Epub ahead of print].
33. BERNATSKI S, JOSEPH L, BOIVIN JF et al.: The relationship between cancer and medication exposures in systemic lupus erythematosus: a case-cohort study. Ann Rheum Dis 2008; 67: 74-9.
34. BERNATSKI S, RAMSEY-GOLDMAN R, JOSEPH L et al.: Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis doi:10.1136/annrheumdis-2012-202099.
35. BERNATSKY S, RAMSEY-GOLDMAN R, CLARKE AE: Malignancy in systemic lupus erythematosus: what have we learned? Best Practice & Research Clinical Rheumatology 2009; 23: 539-47.
36. CHAMBERS SA, RAINE R, RAHMAN A, ISENBERG D: Why do patients with systemic lupus erythematosus take or fail to take their prescribed medications? A qualitative study in a UK cohort. Rheumatology 2009; 48: 266-71.
37. SHARON E, KAPLAN D, DIAMOND HS: Exacerbation of systemic lupus erythematosus after withdrawal of azathioprine therapy. N Engl J Med 1973; 288: 122-4.
38. TSAKONAS E, JOSEPH L, ESDAILE JM et al.: A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 1998; 7: 80-5.
39. BOOTSMA H, SPRONK P, DERKSEN R et al.: Prevention of relapses in systemic lupus erythematosus. Lancet 1995; 345: 1595-9.
40. TSENG CE, BUYON JP, KIM M et al.: The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 200; 54: 3623-32.
41. BARR SG, ZONANA-NACACH A, MADGER LS, PETRI M: Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 2682-8.
42. NIKPOUR M, UROWITZ MB, IBANEZ D, GLADMAN DD: Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum 2009; 61: 1152-8.
43. ESDAILE JM, ABRAHAMOWICZ M, JOSEPH L, MacKENZIE T, LI Y, DANOFF D: Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. Arthritis Rheum 1996; 39: 370-8.
44. MOSCA M, TANI C, ARINGER M et al.: European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010; 69: 1269-74.
45. LaROCHELLE GE, Jr., LaROCHELLE AG, RATNER RE, BORENSTEIN DG: Recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving lowdose prednisone. Am J Med 1993; 95: 258-64.